Trial Profile
A Double-masked Study of DE-111 Ophthalmic Solution Versus Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% in Patients With Primary Open Angle Glaucoma or Ocular Hypertension -Phase 3, Confirmatory Study-
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Jun 2015
Price :
$35
*
At a glance
- Drugs Tafluprost/timolol (Primary) ; Tafluprost; Timolol
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Registrational; Therapeutic Use
- Sponsors Santen Pharmaceutical
- 24 Apr 2014 New trial record